Interstitial high-dose-rate brachytherapy as a boost in synchronous prostate and rectal cancer treatment: case report and literature review.

brachytherapy chemoradiotherapy multidisciplinary treatment prostate cancer rectal cancer synchronous cancers

Journal

Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 06 12 2019
accepted: 16 03 2020
entrez: 13 5 2020
pubmed: 13 5 2020
medline: 13 5 2020
Statut: ppublish

Résumé

Prostate and colorectal cancers are the first and the third most popular malignancies in male population, in which some patients may develop these tumors metachronously or synchronously. At present, there are no standard recommendations, and oncologists need to provide an optimal management for two different cancers with an acceptable risk of possible treatment of adverse effects. This case report presents the treatment of a 61-year-old patient suffering from synchronous prostate and rectal cancer. Both malignancies were locally advanced, histologically proven, and defined as cT2cN0M0 stage prostate and cT3N2M0 stage rectal adenocarcinoma. Multidisciplinary treatment team decided on synchronous radical treatment of both malignancies. The patient was qualified to long-term androgen deprivation therapy (ADT) and preoperative chemoradiation, with a total dose of 50.4 Gy in 28 fractions delivered with intensity modulated radiation therapy/image-guided radiation therapy (IMRT/IGRT) to a proper prostatic and rectal gross and nodal clinical target volume (CTV) with concurrent 5-fluorouracil. Additional dose of 15 Gy in a single fraction was delivered to prostate with interstitial HDR brachytherapy within a week after external beam radiotherapy (EBRT). After 8 weeks, the patient underwent sphincter-sparing surgery, with total mesorectal excision. Treatment tolerance was good, and genitourinary toxicity was not observed until now. At present, the patient is 45 months after completion of chemoradiation and surgery. Current prostate specific antigen (PSA) level is < 0.003 ng/ml, with no evidence of locoregional recurrence or distant metastases. Patient completed long-term ADT. High-dose-rate (HDR) brachytherapy as a boost seems to be well-tolerated and effective option for delivering proper treatment dose to prostate in case of simultaneous treatment of rectal and prostate cancer.

Identifiants

pubmed: 32395143
doi: 10.5114/jcb.2020.94585
pii: 40414
pmc: PMC7207231
doi:

Types de publication

Case Reports

Langues

eng

Pagination

181-187

Informations de copyright

Copyright © 2020 Termedia.

Déclaration de conflit d'intérêts

This study was funded by a statutory subsidy by the Polish Ministry of Science and Higher Education as part of grant SUB.C280.19.050 (record numbers in the Simple system). Authors report no conflict of interest.

Références

Radiother Oncol. 2018 Apr;127(1):49-61
pubmed: 29496279
Oncol Lett. 2011 Sep 1;2(5):817-819
pubmed: 22866133
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285
pubmed: 28262473
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):269-76
pubmed: 19775833
Radiother Oncol. 2015 Jun;115(3):295-300
pubmed: 26028229
Rep Pract Oncol Radiother. 2018 Sep-Oct;23(5):458-461
pubmed: 30224901
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-1453
pubmed: 27325475
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):286-295
pubmed: 28433432
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101
pubmed: 10192361
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
J Contemp Brachytherapy. 2014 Oct;6(3):323-30
pubmed: 25337138
Br J Radiol. 2016;89(1057):20150292
pubmed: 26539631
J Clin Med Res. 2014 Jun;6(3):157-61
pubmed: 24734141
Adv Radiat Oncol. 2019 Apr 18;4(4):631-640
pubmed: 31673656
Brachytherapy. 2019 Mar - Apr;18(2):186-191
pubmed: 30638912
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):874-83
pubmed: 26104940
Nat Clin Pract Oncol. 2005 May;2(5):271-4; quiz 1 p following 274
pubmed: 16264963
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):715-22
pubmed: 24521685
Cancer Treat Rev. 2018 Nov;70:265-271
pubmed: 30326422
Pract Radiat Oncol. 2012 Oct-Dec;2(4):e77-e84
pubmed: 24674189
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
Brachytherapy. 2012 Jan-Feb;11(1):20-32
pubmed: 22265435
Radiother Oncol. 2016 Aug;120(2):195-201
pubmed: 27528121
Eur Urol. 2017 Nov;72(5):738-744
pubmed: 28688613

Auteurs

Katarzyna Konat-Bąska (K)

Wroclaw Comprehensive Cancer Center, Poland.
Department of Oncology, Wroclaw Medical University, Poland.

Adam Chicheł (A)

Brachytherapy Department, Greater Poland Cancer Center, Poznan', Poland.

Urszula Staszek-Szewczyk (U)

Wroclaw Comprehensive Cancer Center, Poland.
Department of Oncology, Wroclaw Medical University, Poland.

Adam Maciejczyk (A)

Wroclaw Comprehensive Cancer Center, Poland.
Department of Oncology, Wroclaw Medical University, Poland.

Rafał Matkowski (R)

Wroclaw Comprehensive Cancer Center, Poland.
Department of Oncology, Wroclaw Medical University, Poland.

Classifications MeSH